Saint Peter's University Hospital

Running trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

  NCT07723963· Phase 2/3· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Source

• Recruiting

  A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

  NCT06410209· Phase 2· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· Source

• Recruiting

  A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

  NCT05382338· Phase 3· Source

• Recruiting

  Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  NCT05334069· Source

• Active, not recruiting

  A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

  NCT04939597· Phase 3· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· Source

• Recruiting

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  NCT05235165· Phase 3· Source

• Active, not recruiting

  To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

  NCT04597359· Phase 2· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Source

• Active, not recruiting

  Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04320888· Phase 2· Source

• Recruiting

  A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT04546399· Phase 2· Source

• Active, not recruiting

  Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

  NCT04089358· Phase 3· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

  NCT04616326· Phase 3· Source

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Source

• Active, not recruiting

  Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· Phase 2· Source

• Recruiting

  A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  NCT04293562· Phase 3· Source

• Active, not recruiting

  Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

  NCT04195555· Phase 2· Source

• Recruiting

  Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

  NCT04239573· Source

• Recruiting

  Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  NCT03959085· Phase 3· Source

• Active, not recruiting

  Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488· Phase 3· Source

• Active, not recruiting

  A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· Phase 3· Source

• Active, not recruiting

  Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03698994· Phase 2· Source

• Active, not recruiting

  Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292· Phase 2· Source

• Active, not recruiting

  Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03210714· Phase 2· Source

• Recruiting

  Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  NCT03126916· Phase 3· Source

• Active, not recruiting

  Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652· Phase 2· Source

• Active, not recruiting

  Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579· Phase 2· Source

• Active, not recruiting

  Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  NCT03213704· Phase 2· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Source

• Active, not recruiting

  Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620· Phase 2· Source

• Active, not recruiting

  Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

  NCT02981628· Phase 2· Source

• Recruiting

  Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181· Phase 3· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435· Phase 3· Source

• Recruiting

  Project: Every Child for Younger Patients With Cancer

  NCT02402244· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· Source

• Active, not recruiting

  Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

  NCT02166463· Phase 3· Source

• Active, not recruiting

  Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

  NCT02101853· Phase 3· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161· Phase 3· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

  NCT02112916· Phase 3· Source

• Active, not recruiting

  Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967· Phase 3· Source

• Active, not recruiting

  Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

  NCT01169337· Phase 3· Source

• Active, not recruiting

  RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  NCT00956007· Phase 3· Source

• Recruiting

  Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  NCT00736749· Source

• Recruiting

  Pompe Disease Registry Protocol

  NCT00231400· Source

Showing 50 of 52.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers17 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Acute myeloid leukaemia3 recruiting
• Kidney cancer3 recruiting
• Down syndrome2 recruiting
• Lung cancer2 recruiting
• Neuroblastoma2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Epilepsy1 recruiting
• Fabry disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gaucher disease1 recruiting
• Hearing loss1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Pompe disease1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· Source

• Completed

  Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

  NCT05004337· Source

• Completed

  Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

  NCT03963739· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· Source

• Completed

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250· Phase 2· Source

• Completed

  Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678· Phase 2· Source

• Completed

  Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691· Phase 2· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· Source

• Completed

  Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

  NCT01996865· Phase 3· Source

• Terminated

  Connect® Myeloid Disease Registry

  NCT01688011· Source

• Completed

  Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

  NCT01546987· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· Source

• Completed

  Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

  NCT01503632· Phase 3· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source

• Completed

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

  NCT00392327· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Source

• Completed

  Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745· Source

• Completed

  Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

  NCT00026312· Phase 3· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Source

Trial sites

• Saint Peter's University Hospital82 trials
• Saint Peter's University Hospital - New Brunswick- Site Number : 8400163 trials
• St. Peter's University Hospital1 trial